Refine by
Patient Blood Articles & Analysis
57 news found
Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term performance of brain-computer interfaces ...
The rapid, tumor-naïve plasma based test is designed to detect circulating tumor DNA (ctDNA) in the blood of patients with early stage colorectal cancer (CRC) after curative intent surgery. xM was developed using the company’s multimodal database and advanced machine learning algorithms to accurately classify tumor fragments from non-tumor fragments, ...
ByTempus
This yields rapid and highly sensitive results, enabling researchers to detect and quantify viral RNA swiftly and accurately in a patient's blood, serum, or other relevant samples. Moreover, the kits offer unparalleled reliability, with precise and consistent performance across diverse sample types. ...
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length ...
This year's certified measures include Hemoglobin A1c Control for Patients with Diabetes (HBD), Blood Pressure Control for Patients with Diabetes (BPD), Kidney Health Evaluation for Patients with Diabetes (KED), Lead Screening in Children (LSC), and Child and Adolescent Well-Care Visits (WCV). ...
Healthcare providers claimed they are recommending blood glucose management apps to only 25 percent of their patients, while 55% of patients who reported having a blood glucose meter that includes an app claimed they use the app regularly. ...
ByLifeScan
Entegrion Announces CE Mark for Point of Care System for Blood Coagulation Monitoring. Regulatory clearance makes Entegrion’s innovative point of care diagnostic instrument for viscoelastic coagulation testing available to clinicians in Europe. ...
What are the challenges with traditional blood testing for both payers and members? Traditional blood testing has not kept up with consumer preferences and innovations in health care. ...
Compared to non-fractional lasers, the advantages are less damage, faster patient recovery after treatment, and less downtime. The system is equipped with a high-speed graphic scanner, which can scan and output graphics of different shapes, and provide personalized treatment plans according to the needs of different patients. ...
The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows ...
Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for ...
Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients with severe paralysis, at Mount Sinai Hospital in New York. ...
The test, which only requires patients to complete a simple blood draw, is intended for adults age 45 and older who are not up to date with recommended screening guidelines, show no symptoms, and are at average risk for CRC. ...
Yaranov, M.D., Baptist Heart Institute, Memphis, TN stated, “Significant derangement of blood volume persists in ambulatory patients with LVAD”, noting that 91% of patients studied had an abnormal blood volume. ...
I believe the benefits of our innovative blood purification technology will make a positive impact on the lives of treated patients throughout the region,” said Whittemore. ...
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a small mesh-like ...
I am thrilled to join Bluejay because it is seeking to offer healthcare providers the opportunity to conduct important tests using whole blood for patients with life threatening conditions in a near-patient setting. ...
Historically many patients have opted for blood thinners to reduce this risk, but these come with an increased risk of bleeding and can require dietary restrictions and frequent blood tests for monitoring. ...
Prospective registrational study expected to enroll nearly 10,000 patients in 36 months REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly ...